Related Experiment Video

Updated: Aug 9, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

MxA protein induction in MS patients treated with intramuscular IFNbeta-1a

A M Vallittu1, A A Salmi, J P Erälinna

  • 1Department of Virology, University of Turku, Finland. anna-maija.vallittu@utu.fi

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|April 8, 2006
PubMed

Insights

Intramuscular interferon-beta-1a (Avonex) therapy for multiple sclerosis (MS) patients showed sustained effects on lymphocytes, with weaker MxA protein induction compared to subcutaneous interferon-beta-1a (Rebif). No neutralizing antibodies developed, but some binding antibodies appeared in long-term patients.

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Interferon-beta (IFNbeta) therapy is used for multiple sclerosis (MS).
  • Different IFNbeta preparations vary in antigenicity and biologic activity.
  • MxA protein induction in leukocytes is a marker for IFNbeta's therapeutic effects.

Purpose of the Study:

  • To prospectively evaluate MxA protein induction and antibody development (binding and neutralizing) in MS patients receiving intramuscular IFNbeta-1a (Avonex).
  • To compare these effects with subcutaneous IFNbeta-1a (Rebif).

Main Methods:

  • Prospective study of 9 relapsing-remitting MS (RRMS) patients on intramuscular IFNbeta-1a for one year.
  • Included 9 RRMS patients on long-term Avonex (1-3.5 years).
  • Measured MxA protein levels and assessed binding antibodies (BAb) and neutralizing antibodies (NAb).

Main Results:

  • None of the 18 patients developed NAb.
  • Three long-term patients developed BAb.
  • MxA protein induction was weaker compared to Rebif, but the stimulation index remained elevated.
  • Weekly intramuscular dosing demonstrated a sustained effect on lymphocytes.

Conclusions:

  • Intramuscular IFNbeta-1a provides sustained lymphocyte effects in MS patients.
  • Differences in leukocyte stimulation may explain variations in therapeutic outcomes between IFNbeta therapies.
  • Monitoring MxA protein is crucial for assessing IFNbeta treatment efficacy.

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...